Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of fidaxomicin in IBD subjects with Clostridium difficile infection
2014-003002-32Phase 3Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fidaxomicin in Clostridioides difficile colitis (CDI) and inflammatory bowel disease (IBD), sponsored by Astellas Pharma. Primary endpoints: Plasma pharmacokinetics of fidaxomicin and Plasma pharmacokinetics of OP-1118. Started Feb 2015; status: terminated.
02
Drugs
fidaxomicin
03
Conditions
Clostridioides difficile colitis (CDI)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2014-003002-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003002-32.